ImmunoScape’s CEO Choon-Peng Ng is featured in Endpoints. Endpoints highlights ImmunoScape’s $14M funding round, our use of machine learning to discover TCR-T cell therapies focused on solid tumors, and our progress toward the clinic.
You can read the full interview at the link below: https://endpts.com/tcr-upstart-gets-fresh-funding-as-it-looks-to-charge-toward-the-clinic/